Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, 11751 Nasr City, Cairo, Egypt.
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, 11751 Nasr City, Cairo, Egypt.
Spectrochim Acta A Mol Biomol Spectrosc. 2022 May 5;272:121012. doi: 10.1016/j.saa.2022.121012. Epub 2022 Feb 7.
Simeprevir and sofosbuvir are direct-acting antiviral drugs approved for the treatment of chronic HCV infection. Reports demonstrate the similarities between HCV and SARS-CoV-2 in terms of structure and replication mechanism. Therefore, it is suggested that a combination of simeprevir and sofosbuvir may be considered for COVID-19 patients. To date, no spectrophotometric methods have been published for quantitative analysis of simeprevir and sofosbuvir in combination. In this work, two simple spectrophotometric methods allowed quantitative analysis of the studied drugs in the mixed form. The zero-order direct method allowed quantitative analysis of simeprevir at 333 nm, with sofosbuvir showing zero absorbance values. The dual wavelength method allowed quantitative analysis of sofosbuvir by measuring the difference in absorbance values at 259.40 and 276 nm, where the difference in absorbance values of simeprevir was zero. With the applied methods, the investigated drugs in the mixtures and tablets prepared in the laboratory were successfully analyzed quantitatively with acceptable results.
西美瑞韦和索磷布韦是批准用于治疗慢性丙型肝炎感染的直接作用抗病毒药物。有报道表明丙型肝炎病毒和严重急性呼吸综合征冠状病毒 2 在结构和复制机制方面具有相似性。因此，建议考虑将西美瑞韦和索磷布韦联合用于 COVID-19 患者。迄今为止，尚未发表用于定量分析联合使用的西美瑞韦和索磷布韦的分光光度法。在这项工作中，两种简单的分光光度法允许对研究药物以混合形式进行定量分析。零阶直接法允许在 333nm 处对西美瑞韦进行定量分析，而索磷布韦的吸光度值为零。双波长法允许通过测量在 259.40nm 和 276nm 处的吸光度差值来对索磷布韦进行定量分析，其中西美瑞韦的吸光度差值为零。应用所提出的方法，可以成功地对混合物和实验室制备的片剂中的研究药物进行定量分析，结果令人满意。
